HRP20211086T1 - Pomoćna farmaceutska sredstva s kontroliranim otpuštanjem i slojeviti kompleks za uključivanje ciklodekstrina - Google Patents
Pomoćna farmaceutska sredstva s kontroliranim otpuštanjem i slojeviti kompleks za uključivanje ciklodekstrina Download PDFInfo
- Publication number
- HRP20211086T1 HRP20211086T1 HRP20211086TT HRP20211086T HRP20211086T1 HR P20211086 T1 HRP20211086 T1 HR P20211086T1 HR P20211086T T HRP20211086T T HR P20211086TT HR P20211086 T HRP20211086 T HR P20211086T HR P20211086 T1 HRP20211086 T1 HR P20211086T1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclodextrin
- pharmaceutical agent
- auxiliary pharmaceutical
- guest molecule
- molecule
- Prior art date
Links
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims 25
- 229920000858 Cyclodextrin Polymers 0.000 title claims 21
- 238000013270 controlled release Methods 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 12
- 102000013142 Amylases Human genes 0.000 claims 8
- 108010065511 Amylases Proteins 0.000 claims 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 239000004382 Amylase Substances 0.000 claims 4
- 235000019418 amylase Nutrition 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000005456 glyceride group Chemical group 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- 230000000717 retained effect Effects 0.000 claims 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000000593 degrading effect Effects 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
- C12N9/1074—Cyclomaltodextrin glucanotransferase (2.4.1.19)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5112—Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01054—Cyclomaltodextrinase (3.2.1.54), i.e. cyclodextrinase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Materials Engineering (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
Claims (14)
1. Pomoćno farmaceutsko sredstvo za primjenu kompleksa koji uključuje ciklodekstrin, koje obuhvaća: alfa ciklodekstrin koji ima šupljinu;
molekula maslačne kiseline, ili njen glicerid, koji je barem djelomično zadržan kao gost-molekula unutar šupljine ciklodekstrina, koja tvori kompleks koji uključuje ciklodekstrin;
farmaceutski prihvatljiv nosač za kompleks koji uključuje ciklodekstrin, pri čemu je gost-molekula stabilno zadržana putem ciklodekstrina unutar farmaceutski prihvatljivog nosača; i,
mikrobni enzim amilaze koji ima aktivnost razgradnje ciklodekstrina koji može razložiti ciklodekstrin a da pri tome zadržava gost-molekulu, pri čemu je mikrobni enzim amilaze ko-formuliran s kompleksom koji uključuje ciklodekstrin tako da je aktivnost razgradnje ciklodekstrina aktivirana na oralnoj primjeni pomoćnog farmaceutskog sredstva ljudskom pacijentu tako da se otpusti gost-molekula iz šupljine ciklodekstrina.
2. Pomoćno farmaceutsko sredstvo za primjenu sukladno patentnom zahtjevu 1, pri čemu je ta amilaza bakterijska amilaza.
3. Pomoćno farmaceutsko sredstvo za primjenu sukladno bilo kojem od patentnih zahtjeva 1 ili 2, pri čemu je taj ciklodekstrin hidrofobni alkilirani ciklodekstrin.
4. Pomoćno farmaceutsko sredstvo za primjenu sukladno bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je taj ciklodekstrin mješoviti metilirani/etilirani ciklodekstrin.
5. Pomoćno farmaceutsko sredstvo za primjenu sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je to pomoćno farmaceutsko sredstvo za primjenu formulirano za usporeno otpuštanje molekule maslačne kiseline ili njenog glicerida.
6. Pomoćno farmaceutsko sredstvo za primjenu sukladno patentnom zahtjevu 5, nadalje obuhvaća lipazu.
7. Pomoćno farmaceutsko sredstvo za primjenu sukladno bilo kojem od patentnih zahtjeva 1 do 6, za uporabu u liječenju gastrointestinalnog poremećaja.
8. Pomoćno farmaceutsko sredstvo za primjenu sukladno patentnom zahtjevu 7, pri čemu je taj poremećaj kolitis, divertikulitis, Chronova bolest, upalna bolest crijeva, sindrom nervoznih crijeva, upala povezana s otvorom za stomu ili granulacija povezana s otvorom za stomu.
9. Postupak formuliranja pomoćnog farmaceutskog sredstva za primjenu kompleksa koji uključuje ciklodiekstrin, koji sadrži:
osiguravanje alfa ciklodekstrina koji ima šupljinu;
osiguravanje molekule maslačne kiseline, ili njenog glicerida, koja je barem djelomično zadržana kao gost-molekula unutar šupljine ciklodekstrina, koja stvara kompleks koji uključuje ciklodekstrin;
osiguravanje farmaceutski prihvatljivog nosača za kompleks koji uključuje ciklodekstrin, pri čemu je gost-molekula stabilno zadržana pomoću ciklodekstrina unutar farmaceutski prihvaltjivog nosača; i,
osiguravanje mikrobnog enzima amilaze koji ima aktivnost razgradnje ciklodekstrina koja može razgraditi ciklodekstrin pri čemu zadržava gost-molekulu, pri čemu je mikrobni enzim amilaze ko-formuliran s kompleksom koji uključuje ciklodekstrin tako da je aktivnost razgradnje ciklodekstrina aktivirana na oralnoj primjeni pomoćnog farmaceutskog sredstva na ljudskom pacijentu tako da se otpusti gost-molekula iz šupljine ciklodekstrina.
10. Postupak sukladno patentnom zahtjevu 9, pri čemu je ta amilaza bakterijska amilaza.
11. Postupak sukladno bilo kojem od patentnih zahtjeva 9 ili 10, pri čemu je ciklodekstrin hidrofobni alkilirani ciklodekstrin.
12. Postupak sukladno bilo kojem od patentnih zahtjeva 9 do 11, pri čemu je ciklodekstrin mješoviti metilirani/etilirani ciklodekstrin.
13. Postupak sukladno bilo kojem od patentnih zahtjeva 9 do 12, pri čemu je pomoćno farmaceutsko sredstvo za primjenu formulirano za zadržano otpuštanje molekule maslačne kiseline ili njenog glicerida.
14. Pomoćno farmaceutsko sredstvo za primjenu sukladno bilo kojem od patentnih zahtjeva 1 do 6, za uporabu u liječenje poremećaja iz spektra autizma.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291202P | 2016-02-04 | 2016-02-04 | |
US15/232,647 US20170224841A1 (en) | 2016-02-04 | 2016-08-09 | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
US15/285,264 US20170224842A1 (en) | 2016-02-04 | 2016-10-04 | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
US201762444036P | 2017-01-09 | 2017-01-09 | |
PCT/US2017/016583 WO2017136775A1 (en) | 2016-02-04 | 2017-02-03 | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
EP17748308.8A EP3411047B1 (en) | 2016-02-04 | 2017-02-03 | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211086T1 true HRP20211086T1 (hr) | 2021-10-15 |
Family
ID=59500049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211086TT HRP20211086T1 (hr) | 2016-02-04 | 2021-07-07 | Pomoćna farmaceutska sredstva s kontroliranim otpuštanjem i slojeviti kompleks za uključivanje ciklodekstrina |
Country Status (18)
Country | Link |
---|---|
US (2) | US11633448B2 (hr) |
EP (3) | EP3411047B1 (hr) |
JP (3) | JP6884420B2 (hr) |
KR (1) | KR20190005823A (hr) |
CN (2) | CN115154619A (hr) |
AU (2) | AU2017214669B2 (hr) |
CA (1) | CA3012837A1 (hr) |
CY (1) | CY1124822T1 (hr) |
DK (1) | DK3411047T3 (hr) |
ES (1) | ES2878580T3 (hr) |
HR (1) | HRP20211086T1 (hr) |
HU (1) | HUE055157T2 (hr) |
LT (1) | LT3411047T (hr) |
PL (1) | PL3411047T3 (hr) |
PT (1) | PT3411047T (hr) |
RS (1) | RS62097B1 (hr) |
SI (1) | SI3411047T1 (hr) |
WO (1) | WO2017136775A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3012837A1 (en) * | 2016-02-04 | 2017-08-10 | Czap Research And Development, Llc | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
WO2018053358A1 (en) * | 2016-09-16 | 2018-03-22 | Cydex Pharmaceuticals, Inc. | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin |
CA3099762A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Methods of manufacturing amino acid compositions |
CN111183989A (zh) * | 2018-11-14 | 2020-05-22 | 北京中以新农高科商务咨询有限公司 | 包含胶囊化挥发性精油和溶解在其中的聚合物的农用制剂 |
KR102200694B1 (ko) * | 2018-11-29 | 2021-01-08 | 한국세라믹기술원 | 소수성 활성성분의 안정화 방법 및 안정화된 활성성분을 함유하는 화장료 조성물 |
WO2020168421A1 (en) * | 2019-02-19 | 2020-08-27 | Agrima Scientific Corp. | Cyclodextrin inclusion complexes of cannabis extracts |
CN110123876A (zh) * | 2019-05-30 | 2019-08-16 | 汉义生物科技(北京)有限公司 | 一种含有非精神活性大麻素的包合物及其制备方法 |
EP4125830A4 (en) * | 2020-03-23 | 2023-12-20 | Czap Research And Development, LLC | VEHICLES OF ORAL CYCLODEXTRIN TERPENE INCLUSION COMPLEXES |
CN111298108A (zh) * | 2020-04-10 | 2020-06-19 | 亘元(天津)生物医药科技有限公司 | 一种儿童长效型复合酶消毒组合物及应用 |
EP4285989A1 (en) | 2021-03-25 | 2023-12-06 | Cyclochem Bio Co., Ltd. | Intestinal tract function-improving agent |
IT202200008894A1 (it) * | 2022-05-03 | 2023-11-03 | Biodue S P A | Composizione nutriceutica comprendente citicolina, vitamina D3 e olio di canapa. |
CN115039742B (zh) * | 2022-05-24 | 2023-08-29 | 江苏宁录科技股份有限公司 | 一种草地贪夜蛾性信息素双重缓释诱芯及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2453829C2 (de) | 1974-11-13 | 1983-04-07 | Siemens AG, 1000 Berlin und 8000 München | Verfahren zur Herstellung von Additiven und ihre Verwendung als Glanzbildner |
HU176215B (en) * | 1978-01-27 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1 |
CA1222742A (en) | 1981-01-23 | 1987-06-09 | Harry P. Jones | INCLUSION COMPLEX OF .beta.-CYCLODEXTRIN AND DIGOXIN |
JPS5944318A (ja) * | 1982-09-04 | 1984-03-12 | Riken Kagaku Kogyo Kk | サイクロデキストリン難脱包接物質よりの脱包接法 |
US4538920A (en) | 1983-03-03 | 1985-09-03 | Minnesota Mining And Manufacturing Company | Static mixing device |
JPH0819004B2 (ja) | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | 徐放性医薬製剤 |
CA1321192C (en) | 1988-04-20 | 1993-08-10 | Abdul Majid | Inclusion complexes of cyclodextrins by agglomeration |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
CA2013485C (en) | 1990-03-06 | 1997-04-22 | John Michael Gardlik | Solid consumer product compositions containing small particle cyclodextrin complexes |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
ES2118673T3 (es) * | 1996-10-29 | 2001-04-16 | Staroil Ltd | Composiciones solubles en la boca que contienen n-acetilcisteina y ciclodextrina. |
US6065645A (en) | 1997-04-01 | 2000-05-23 | Discus Dental Impressions, Inc. | Double-barreled syringe with detachable locking mixing tip |
CN1176784A (zh) * | 1997-07-24 | 1998-03-25 | 北京路德有限责任公司 | 对乙酰氨基酚咀嚼片的制造方法及其产品 |
DE19911097A1 (de) * | 1999-03-12 | 2000-09-14 | Basf Ag | Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen |
EP1337648B1 (de) * | 2000-11-28 | 2007-09-19 | Henkel Kommanditgesellschaft auf Aktien | Cyclodextrin -glucanotransferase(cg tase) aus bacillus agaradherens(dsm 9948)sowie wasch-und reinigungsmittel mit dieser neuen cyclodextrin-glucanotransferase |
US6566401B2 (en) * | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
FI113340B (fi) * | 2002-02-20 | 2004-04-15 | Tomi Jaervinen | Uudet luonnon syklodekstriinin kompleksit |
US7001893B2 (en) | 2002-10-28 | 2006-02-21 | Council Of Scientific And Industrial Research | Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof |
KR100675081B1 (ko) * | 2003-03-06 | 2007-01-26 | 주식회사 서울제약 | 아세틸시스테인 함유 경구용 제제 |
WO2006058153A1 (en) | 2004-11-23 | 2006-06-01 | Smith & Nephew, Inc. | Composite mixer |
MX2007015871A (es) | 2005-06-13 | 2008-03-04 | Cargill Inc | Complejos de inclusion de ciclodextrina y metodos para preparar los mismos. |
US20070003528A1 (en) | 2005-06-29 | 2007-01-04 | Paul Consigny | Intracoronary device and method of use thereof |
EP1746045B1 (de) | 2005-07-22 | 2009-09-16 | Dentaco Dentalindustrie- und Marketing GmbH | Mehrkammerausgabevorrichtung |
US20070072146A1 (en) | 2005-09-29 | 2007-03-29 | Dentsply Research And Development Corp. | Dispensing syringe having multiple barrels for discharging a dental composition |
US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
JP5087072B2 (ja) | 2006-03-24 | 2012-11-28 | メッドミックス システムズ アーゲー | 取外し可能に取付けできる付属部品を有する送出装置 |
CN100411688C (zh) | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
CN101535315A (zh) * | 2006-10-13 | 2009-09-16 | 辉瑞有限公司 | 用作家畜动物的同化激素类药的杂环化合物 |
WO2009006898A1 (en) | 2007-07-11 | 2009-01-15 | Fertin Pharma A/S | Stable medicated chewing gum comprising cyclodextrin inclusion complex |
KR100929920B1 (ko) | 2007-09-05 | 2009-12-04 | 주식회사 마크로케어 | 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도 |
US20100069536A1 (en) * | 2008-07-17 | 2010-03-18 | Sau Arjun C | Process for tailoring water-borne coating compositions |
CN105687177A (zh) * | 2009-07-15 | 2016-06-22 | 小利兰·斯坦福大学托管委员会 | N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 |
US20150217896A1 (en) | 2010-02-11 | 2015-08-06 | Clemson University | Packaging materials derived from renewable resources and including a cyclodextrin inclusion complex |
ES2426978T3 (es) | 2010-10-21 | 2013-10-28 | Sulzer Mixpac Ag | Dispositivo de distribución doble |
CN102058536A (zh) * | 2011-01-14 | 2011-05-18 | 四川大学 | 槲皮素羟丙基β-环糊精包和物脂质体及其制备方法和用途 |
PL2976946T3 (pl) | 2011-03-27 | 2017-12-29 | Cellresin Technologies, Llc | Kompozycje cyklodekstryny, wyroby i sposoby |
US20140315780A1 (en) | 2011-05-05 | 2014-10-23 | Jas Pal Singh Badyal | Product |
KR101794242B1 (ko) | 2011-06-07 | 2017-11-07 | 임병갑 | 서방성 경구용 액상 제제 |
AU2012290987B2 (en) * | 2011-08-02 | 2017-04-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
WO2014031982A2 (en) | 2012-08-24 | 2014-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating pain |
AU2013327489B2 (en) | 2012-10-02 | 2018-01-04 | Allergan, Inc. | Dermal filler hydrogels with vitamin A/cyclodextrin inclusion complexes |
EP3152297A4 (en) | 2014-06-04 | 2018-01-31 | Protokinetix, Inc. | Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome |
US9421793B2 (en) | 2014-06-26 | 2016-08-23 | Cellresin Technologies, Llc | Electrostatic printing of cyclodextrin compositions |
US10098964B2 (en) * | 2015-03-12 | 2018-10-16 | The Board Of Trustees Of The University Of Illinois | Inclusion complexes and methods for making the same |
US20170224842A1 (en) | 2016-02-04 | 2017-08-10 | Czap Research And Development, Llc | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
CA3012837A1 (en) | 2016-02-04 | 2017-08-10 | Czap Research And Development, Llc | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
-
2017
- 2017-02-03 CA CA3012837A patent/CA3012837A1/en active Pending
- 2017-02-03 KR KR1020187025497A patent/KR20190005823A/ko unknown
- 2017-02-03 EP EP17748308.8A patent/EP3411047B1/en active Active
- 2017-02-03 EP EP22166026.9A patent/EP4098282A1/en active Pending
- 2017-02-03 HU HUE17748308A patent/HUE055157T2/hu unknown
- 2017-02-03 SI SI201730849T patent/SI3411047T1/sl unknown
- 2017-02-03 PL PL17748308T patent/PL3411047T3/pl unknown
- 2017-02-03 PT PT177483088T patent/PT3411047T/pt unknown
- 2017-02-03 CN CN202210863828.4A patent/CN115154619A/zh active Pending
- 2017-02-03 EP EP21163773.1A patent/EP3892303B1/en active Active
- 2017-02-03 RS RS20210885A patent/RS62097B1/sr unknown
- 2017-02-03 JP JP2018560451A patent/JP6884420B2/ja active Active
- 2017-02-03 LT LTEP17748308.8T patent/LT3411047T/lt unknown
- 2017-02-03 DK DK17748308.8T patent/DK3411047T3/da active
- 2017-02-03 CN CN201780017946.0A patent/CN108883125B/zh active Active
- 2017-02-03 AU AU2017214669A patent/AU2017214669B2/en active Active
- 2017-02-03 ES ES17748308T patent/ES2878580T3/es active Active
- 2017-02-03 WO PCT/US2017/016583 patent/WO2017136775A1/en active Application Filing
-
2021
- 2021-04-30 JP JP2021077553A patent/JP7144087B2/ja active Active
- 2021-07-07 HR HRP20211086TT patent/HRP20211086T1/hr unknown
- 2021-07-13 CY CY20211100632T patent/CY1124822T1/el unknown
-
2022
- 2022-02-15 AU AU2022200988A patent/AU2022200988A1/en active Pending
- 2022-05-04 US US17/736,386 patent/US11633448B2/en active Active
- 2022-09-08 JP JP2022142626A patent/JP2022173261A/ja active Pending
-
2023
- 2023-03-15 US US18/184,228 patent/US20230405074A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211086T1 (hr) | Pomoćna farmaceutska sredstva s kontroliranim otpuštanjem i slojeviti kompleks za uključivanje ciklodekstrina | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
WO2016070151A8 (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
WO2015047941A3 (en) | Compositions and methods for treatment and prophylaxis of gastrointestinal diseases | |
PE20230169A1 (es) | Suministro al sistema nervioso central de agentes terapeuticos | |
ECSP077182A (es) | Metodos para el tratamiento de infecciones endobronquiales | |
JP2016507532A5 (hr) | ||
WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
PE20150132A1 (es) | Compuestos d-aminoacidos para enfermedad hepatica | |
NO20073722L (no) | Farmasoystiske sammensetniger omfattende bendamustin | |
AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
PE20120777A1 (es) | Combinacion de un inhibidor de nucleosido polimerasa con un inhibidor de proteasa macrociclica y su uso en el tratamiento de hepatitis c, fibrosis hepatica y funcion hepatica alterada | |
CL2008002852A1 (es) | Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas. | |
BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
BR112017008993A2 (pt) | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | |
CL2015003596A1 (es) | Formulación de liberación modificada | |
HRP20191030T1 (hr) | Bumetanid za liječenje neurodegenerativnih bolesti s parkinsonovim sindromima | |
PE20080673A1 (es) | Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina | |
CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
EA201690659A1 (ru) | Композиции аморфного магнийзамещенного фосфата кальция и их применение | |
CR9991A (es) | Nuevo derivado de pleuromutilina y su uso | |
Auffret et al. | Novel and emerging treatment options for acne vulgaris | |
AR075037A1 (es) | Composiciones farmaceuticas de rendimiento de producto y cumplimiento del paciente superiores |